Medigard Limited announced that Dr. Ian Dixon has agreed to join the Board of Medigard as an Executive Director. Through the review of business and technology opportunities Medigard has engaged with Melbourne-based Dr. Dixon and his Melbourne-based biotechnology team operating as the private Altnia Group. Over the past 12 months the Board of Medigard has been investigating ways that it might broaden its R&D and commercialisation activities in the life-sciences field whilst maintaining and expanding activities in syringe technology and its strategic alliance with SOL-MILLENNIUM. Dr. Dixon is a non-executive director of Noxopharm. He is a major shareholder in Nyrada ­ and including his Altnia PCSK9 drug project. He is also the co-founder of Cynata Inc. in 2011, the company which has become Cynata Therapeutics Ltd.